Import Alert Prompts US Production Expansion for Ranbaxy

The FDA’s import alert for 30 generic drug products made at two Ranbaxy production facilities in India has spurred the company to expand its U.S. manufacturing operations and take an estimated $50.8 million expense against earnings in 2008. “Because of the U.S. FDA ban, we are currently working on site switches to alternative sources in-house and also evaluating U.S. manufacturing capacity expansion in our existing facilities,” Ranbaxy CEO Malvinder Singh said last week.
Drug Industry Daily